Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
'The allowance of this application adds a new tier of patent-protected innovation to our pipeline of non-hallucinogenic neuroplastogens,' said Joseph Tucker, Ph.D., CEO of Enveric. 'Unlike traditional psychedelics that require intensive clinical monitoring due to their hallucinogenic effects, our molecules are designed for frequent, flexible, outpatient dosing, which we expect will be better aligned with patient lifestyles, clinics workflows, and payers established models.'
Non-hallucinogenic psychedelic analogs represent a critical evolution in the treatment of psychiatric and neurological disorders, with potential to treat conditions like depression, anxiety, PTSD, and cognitive impairment, without the operational limitations of hallucinatory experiences. The patent covers both the molecular compositions and their therapeutic applications, further strengthening Enveric's competitive position in this emerging category.
'This achievement reflects Enveric's continued execution on its mission to develop safe and effective neuroplastogenic therapeutics,' Dr. Tucker added. 'Each addition to our intellectual property portfolio helps build a more valuable portfolio of assets for long-term growth.'
The patented molecules were discovered through the Company's proprietary discovery and development platform, which leverages computational and medicinal chemistry to identify optimized, next-generation therapeutic molecules with favorable safety, pharmacology, and scalability profiles.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
14 minutes ago
- Business Insider
‘Don't Bet Against It': $4 Trillion in Sight for Nvidia Stock, Says Investor
Nvidia (NASDAQ:NVDA) has regained much of its shine over the last two months, catching fire once more with a bull run that has boosted its share price by some 50%. Confident Investing Starts Here: This sharp rebound came after a rare rough patch for the AI chipmaker earlier in 2025, when the stock struggled under the weight of tariff shocks, export restrictions, and concerns over reduced capex spending by hyperscalers. The tide began to turn as geopolitical tensions eased and major cloud players reaffirmed their investment plans, restoring confidence in the AI infrastructure boom. A strong earnings report and bullish guidance in late May further reinforced that momentum. However, even with the renewed optimism, not all signals are flashing green. Nvidia's revenue growth is beginning to decelerate – a likely outcome given its enormous scale – prompting some investors to question how much upside is still left. Could this be the point where enthusiasm gives way to caution? One investor, known by the pseudonym Cash Flow Venue, thinks the best course of action is to take a deep breath – and enjoy the ride. 'Let go of valuation concerns and wait for a $4 trillion+ valuation,' explains Cash Flow Venue, who urges investors to simply 'follow the money!' Looking at its recent Fiscal Q1 2026 earnings report, Cash Flow Venue cites the company's impressive year-over-year growth of 69% as a sign that Nvidia has no problem generating cash. Meanwhile, the company's EBITDA for the trailing twelve months has grown to some $91 billion, with the pace of the gains outpacing the rise in Nvidia's Enterprise Value. 'Nvidia's bears often forget that its valuation growth wasn't detached from the business growth. Even more, the business grew more dynamically than the valuation,' Cash Flow Venue noted. And there are plenty of drivers to boost additional growth, the investor hastens to add. With its top-tier hardware, CUDA software, and robust finances, Cash Flow Venue believes that CEO Jense Huang's optimism regarding Nvidia's future is certainly justified. With the pole position in the AI race and plenty of momentum on its side, it's an easy decision for this investor. 'A 'strong buy' business with the best capabilities to capitalize on the new 'industrial revolution,'' concludes Cash Flow Venue (To watch Cash Flow Venue's track record, click here) That's the gist on Wall Street as well. With 35 Buy, 4 Hold, and 1 Sell recommendations, NVDA continues to be a consensus Strong Buy. Its 12-month average price target of $172.36 indicates that despite its recent surge, analysts still see an upside of ~21% up ahead. (See NVDA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
24 minutes ago
- Yahoo
Worried About Tesla's Robotaxi? These Two Words From Nvidia CEO Jensen Huang Might Change Your Mind.
Elon Musk sees autonomous driving as a major component of Tesla's future. While the competition in this young industry will be intense, Nvidia CEO Jensen Huang thinks Tesla has an edge. Some on Wall Street have been raising their share price outlooks for Tesla stock, but recent price action suggests now could be a risky time to buy. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) is primarily known for two things: electric vehicles (EV) and energy storage. For years, however, the company's eccentric CEO Elon Musk has been talking about a vision for the company that's rooted in artificial intelligence (AI). Specifically, Musk wants to parlay Tesla's automobile business into a full-fledged robotaxi operation. The prospects of Tesla disrupting ride-hailing, delivery services, and even car rental businesses has investors excited. But just how real is the opportunity? According to Nvidia CEO Jensen Huang, who appears to be a fan of Musk already, Tesla's autonomous driving ambitions are very real. Let's dig into some recent commentary from Huang that should have Tesla bulls cheering. During an April 2024 earnings call, Musk made an interesting point comparing the evolution of automobiles to that of cellphones. He described how the release of the iPhone and Android devices served as an existential shift in the mobile phone business, essentially turning flip phones into relics. Musk went on to predict that "all cars will need to be smart cars" in the future. By "smart car," Musk means cars that are capable of driving themselves. Essentially, he is saying that autonomous driving is the future of the automotive industry, and if legacy manufacturers such as Ford and General Motors don't catch up to what Tesla is developing through its full self-driving software, then "licensing becomes not optional." During an interview with Yahoo! Finance, Huang appeared to echo Musk's sentiment that all cars will eventually be leveraging autonomous driving technology. But the real kicker is what Huang said about Tesla, declaring the company is "far ahead" of the competition. Two of the biggest Tesla bulls on Wall Street are equity research analyst Dan Ives of Wedbush Securities and Ark Invest CEO Cathie Wood. With Tesla's robotaxi launch reportedly on the horizon, Ives got investors excited when he recently declared the "golden age" of autonomous driving has arrived. Perhaps unsurprisingly, Ives also raised his price target to $500 for Tesla stock, implying nearly 53% upside from the stock's closing price on June 10. Considering Alphabet's Waymo already has the lead in robotaxis, combined with existing footprints in the ride-hailing industry from Uber and Lyft, Tesla would appear to have an uphill battle when it comes to acquiring customers and scaling its own autonomous vehicle fleet. Nevertheless, Wood appears to be even more bullish than Ives. The Ark Invest founder recently doubled down on her optimistic case for Tesla with a five-year share price target of $2,600! Tesla has long been a stock that exhibits out-of-the-ordinary behavior. What I mean by that is measuring Tesla based on traditional valuation metrics such as price-to-sales (P/S) or price-to-earnings (P/E) has rarely been useful. The reason is because Tesla stock tends to move based on narratives and less so on concrete financials. Over the last month, shares of Tesla have gained roughly 9% as of June 10. However, within that brief period, the stock had climbed as high as 22% and declined as much as 5%. This is an extreme range of volatility, even for Tesla. Tesla stock started to tick higher throughout May as Musk announced that he's moving on from his public sector duties at the Department of Government Efficiency (DOGE). Investors were happy to hear this as they assumed Musk would refocus on Tesla, a business that's been stagnant for over a year now. On top of that, the expected robotaxi rollout in June likely attracted some investors as well. But over the last week, Tesla stock took a nosedive at one point due to a very public feud between Musk and President Donald Trump -- specifically regarding disagreements the two have on Trump's new spending bill. Just weeks ago, it seemed the upside from the robotaxi launch was already priced into Tesla stock, but now, you could argue this is an opportunity to buy the dip. With this much volatility and so much of it hanging on the robotaxi, I'd wait and see how the launch goes. Long-term scaling of the robotaxi business will require regulatory approvals, making Musk's political feuds all the more relevant. While it's tempting to scoop up shares of Tesla based on positive talking points from prominent figures such as Huang, Ives, and Wood, there's just too many unknowns surrounding the company right now to make it a prudent buy at these prices. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $373,325!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,475!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $649,102!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Nvidia, and Tesla. The Motley Fool has positions in and recommends Alphabet, Nvidia, Tesla, and Uber Technologies. The Motley Fool recommends General Motors and Lyft. The Motley Fool has a disclosure policy. Worried About Tesla's Robotaxi? These Two Words From Nvidia CEO Jensen Huang Might Change Your Mind. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Can Rivian Realistically Return to Growth in 2025?
Rivian's sales have slowed over the past year. The automaker's first major marketing campaign could boost demand. Rivian's R2 launch will be crucial to the company's potential success. These 10 stocks could mint the next wave of millionaires › When many investors turned to find the next Tesla, which is easier said than done, some turned to the young electric vehicle (EV) maker Rivian Automotive (NASDAQ: RIVN). The company had proven capable of manufacturing high-quality vehicles, impressed critics and consumers alike, and inked a massive deal for delivery vans (EDVs) with Amazon -- life was good. Exiting 2023 you could argue Rivian had more momentum than any EV maker out there, but that has since dissipated and left investors wondering if the automaker can return to growth in 2025. The harsh truth is that the automotive industry is extremely competitive, and it takes an automaker with a full lineup to be truly successful. That hampers Rivian's ability to post extreme growth as the company only offers the R1T, R1S, and EDVs. But what's worse is that Rivian's only offerings are aging, and demand for them is waning -- it's been a noticeable trend. So the question facing investors is: Can the automaker return to growth in 2025 before the highly anticipated R2 launch in 2026? Investors in the know understand that Rivian has a small consumer base, but that it's a highly passionate base as well. There are Rivian adventure groups all across social media with consumers planning trips among other things. Rivian is attempting to tap into this passion with its first major marketing push, which the company could certainly use to help stoke demand for its vehicles. "This campaign is about celebrating the people who define what Rivian truly is," said Vice President of Marketing Denise Cherry on Rivian's blog. "Our vehicles are made to empower exploration and adventure, but it's the stories our owners create that give them real soul. For our first 360 brand campaign, we wanted to make sure our owners were the spotlight." Rivian has largely relied on word of mouth and organic growth to spread its brand awareness, but with demand waning over the past year, this marks the right time for the company to try to drive interest and demand for its R1 vehicles. Then it'll be time for the R1 vehicles to hand the baton to the R2 in 2026, which starts at roughly $45,000, or about half the price of Rivian's R1 vehicles. With 155,000 production units annually the R2 will be able to nearly double production of the R1S and R1T. If demand is there, expect deliveries to take off and accelerate through 2026. Investors also can't forget Rivian's big-time move to swap initial production of the R2 from its Georgia plant, which is under construction, to its Illinois plant thanks to an expansion of the factory. It's a move that not only fills production capacity at its original plant, but that saved the company roughly $2.25 billion. The harsh truth is that Rivian is unlikely to return to growth in 2025, unless its marketing campaign works miracles to drive immense demand. The automaker is essentially all-in on its R2, which boasts a much lower-cost bill of materials and improved tech, and will rely on the R2, R3, and R3X to take the company into its next growth stage. The near-term environment for EVs is pessimistic, especially with the current administration pulling support for the EV industry, and Rivian lacks any visible catalysts for the stock in 2025. But investors would be wise to take the long-term approach with Rivian. The company just achieved two consecutive quarters of gross profit and if it executes the production ramp-up of the R2 in 2026, it will be a much better year for investors. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $373,325!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,475!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $649,102!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Daniel Miller has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Tesla. The Motley Fool has a disclosure policy. Can Rivian Realistically Return to Growth in 2025? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
